BC Week In Review | Oct 20, 2017
Company News

PTAB rejects Sanofi and Regeneron's IPR request

On Oct. 4, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected a request from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for an inter partes review of a patent...
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

Buysiders say Amgen Inc. 's aggressive opening offer for Onyx Pharmaceuticals Inc. may have dissuaded other would-be suitors from entering into a bidding war. On Aug. 25 the companies agreed to a purchase price of...
BioCentury | Jul 15, 2013
Finance

Onyx, Alexion add spice

Buysiders say a takeout of Onyx Pharmaceuticals Inc. is inevitable even after the company rejected an unsolicited bid from Amgen Inc. late last month. They believe the final price could come at a hefty premium...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex preclinical data

IMNX published in Nature Medicine the ability of Flt-3 ligand to block cancer in an animal model. The agent did not abolish established cancers after a certain time period had elapsed, but did slow tumor...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex regulatory update

The FDA authorized an expanded label for Novantrone (mitoxantrone) to include the claim that the product, in combination with corticosteroids, can lower levels of prostate-specific antigen (PSA), a marker for prostate cancer. In a pivotal...
BC Week In Review | Apr 15, 2013
Clinical News

Mobist FLT-3 ligand data

IMNX reported that new, fully functional dendritic cells produced by Mobist can be collected and frozen for later use, such as after chemotherapy. The agent transiently increased the number of fully functioning dendritic cells in...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex preclinical data

Researchers reported animal results that demonstrate a role for IL-1 type 1 receptors in bone loss. As presented at the meeting of the American Society for Bone and Mineral Research in Cincinnati, one study investigated...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc. , starting with several new hires, including a CSO from...
BC Week In Review | Dec 5, 2011
Company News

Amgen autoimmune news

Amgen said the U.S. Patent and Trademark Office issued a patent covering the fusion protein that constitutes autoimmune drug Enbrel etanercept. The patent, which expires in 2028, describes the non-soluble proteins and soluble or insoluble...
BioCentury | Dec 5, 2011
Regulation

A PROfessional trial

Cancer companies have struggled to gain FDA approvals based on patient-reported outcomes, or even to get data from a PRO instrument on a drug's label. Incyte Corp. accomplished both in November with Jakafi ruxolitinib for...
Items per page:
1 - 10 of 808
BC Week In Review | Oct 20, 2017
Company News

PTAB rejects Sanofi and Regeneron's IPR request

On Oct. 4, the U.S. Patent and Trademark Office’s Patent Trial and Appeal Board (PTAB) rejected a request from Sanofi (Euronext:SAN; NYSE:SNY) and Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) for an inter partes review of a patent...
BioCentury | Sep 2, 2013
Finance

Amgen's preemptive strike

Buysiders say Amgen Inc. 's aggressive opening offer for Onyx Pharmaceuticals Inc. may have dissuaded other would-be suitors from entering into a bidding war. On Aug. 25 the companies agreed to a purchase price of...
BioCentury | Jul 15, 2013
Finance

Onyx, Alexion add spice

Buysiders say a takeout of Onyx Pharmaceuticals Inc. is inevitable even after the company rejected an unsolicited bid from Amgen Inc. late last month. They believe the final price could come at a hefty premium...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex preclinical data

IMNX published in Nature Medicine the ability of Flt-3 ligand to block cancer in an animal model. The agent did not abolish established cancers after a certain time period had elapsed, but did slow tumor...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex regulatory update

The FDA authorized an expanded label for Novantrone (mitoxantrone) to include the claim that the product, in combination with corticosteroids, can lower levels of prostate-specific antigen (PSA), a marker for prostate cancer. In a pivotal...
BC Week In Review | Apr 15, 2013
Clinical News

Mobist FLT-3 ligand data

IMNX reported that new, fully functional dendritic cells produced by Mobist can be collected and frozen for later use, such as after chemotherapy. The agent transiently increased the number of fully functioning dendritic cells in...
BC Week In Review | Apr 15, 2013
Clinical News

Immunex preclinical data

Researchers reported animal results that demonstrate a role for IL-1 type 1 receptors in bone loss. As presented at the meeting of the American Society for Bone and Mineral Research in Cincinnati, one study investigated...
BioCentury | Jul 2, 2012
Strategy

Revving the engine

After 18 months on the job, EVP of R&D Douglas Williams is making good on his promise to reignite target discovery efforts at Biogen Idec Inc. , starting with several new hires, including a CSO from...
BC Week In Review | Dec 5, 2011
Company News

Amgen autoimmune news

Amgen said the U.S. Patent and Trademark Office issued a patent covering the fusion protein that constitutes autoimmune drug Enbrel etanercept. The patent, which expires in 2028, describes the non-soluble proteins and soluble or insoluble...
BioCentury | Dec 5, 2011
Regulation

A PROfessional trial

Cancer companies have struggled to gain FDA approvals based on patient-reported outcomes, or even to get data from a PRO instrument on a drug's label. Incyte Corp. accomplished both in November with Jakafi ruxolitinib for...
Items per page:
1 - 10 of 808